Alkermes

Company Overview

Alkermes PLC is an Ireland-based global biopharmaceutical company that develops innovative and competitively advantaged medications that can enhance patient outcomes in major therapeutic areas.

Alkermes’s headquarters are located in Dublin, Ireland, and the R&D center is located in Waltham, Mass. The company has manufacturing facilities in Ireland; Athlon, Ohio; and Wilmington, NC. Alkermes’s subsidiaries include Alkermes Science Five Limited, Alkermes Controlled Therapeutic and Daravuta Pharma Ireland Limited. Alkermes reported annual sales of $1,094 million for the financial year 2018.

Alkermes’ diversified portfolio includes more than 20 commercial drug products and a clinical pipeline of product candidates that address CNS disorders, including addiction, schizophrenia, and depression. The company’s five key revenue-generating products are Risperdal, Consta, Invega, Sustenna and Xeplion. The company’s platforms for products include LinkeRx technology, injectable extended-release microsphere technology, oral controlled release (OCR) technology and NanoCrystal technology.

Alkermes primarily focuses in the areas of central nervous system diseases, including depression, addiction, schizophrenia, and multiple sclerosis. It also offers a strong portfolio of drug products, including Vivitrol, Aristada, Xeplion, Invega Sustenna, Trevicta, Invega Trinza, Consta, Risperdal, Fampyra, Ampyra, Bydureon, Alks 7119, Alks 5461, Alks 6428, Alks 8700, Alks 3831 and Alks 4230. It offers a strong portfolio of primary drugs, including risperidone, naltrexone, exenatide, buprenorphine/samidorphan, antidepressant, olanzapine/samidorphan. Its products utilize in the treatment of irritability associated with autism, schizophrenia, opioid dependence, type 2 diabetes, depression and bipolar mania.

The key strategy of Alkermes is developing new partnerships. It associates with Biogen, AstraZenca, Johnson & Johnson and Acorda pharmaceutical organizations and research establishments.

On October 2021, the company received Fast Track designation from the U.S. FDA for nemvaleukin alfa (nemvaleukin), which can be used for the treatment of platinum-resistant ovarian cancer in combination with pembrolizumab.

Financial Highlights (FY 2024)

Company's Business Segments

• Product Sales : The company various products such as VIVITROL, ARISTADA and ARISTADA INITIO and LYBALVI.
• Manufacturing and Royalty : In this segment company offers Long-acting INVEGA products, VUMERITY, RISPERDAL CONSTA and Others.